Duloxetine Poisoning: A Unique Case of Cardiotoxicity by Fikse, Derek J, DO et al.
Lehigh Valley Health Network 
LVHN Scholarly Works 
Department of Emergency Medicine 
Duloxetine Poisoning: A Unique Case of Cardiotoxicity 
Derek J. Fikse DO 
Lehigh Valley Health Network, Derek.Fikse@lvhn.org 
Alexandra Amaducci DO 
Lehigh Valley Health Network, Alexandra.Amaducci@lvhn.org 
Margaret A. Vido DO 
Lehigh Valley Health Network, margaret.vido@lvhn.org 
Robert D. Cannon DO 
Lehigh Valley Health Network, Robert_D.Cannon@lvhn.org 
Kenneth D. Katz MD 
Lehigh Valley Health Network, Kenneth_D.Katz@lvhn.org 
Follow this and additional works at: https://scholarlyworks.lvhn.org/emergency-medicine 
 Part of the Medical Toxicology Commons 
Published In/Presented At 
Fikse, D., Amaducci, A., Vido, M., Cannon, R., & Katz, K. (2021, April). Duloxetine Poisoning: A Unique Case 
of Cardiotoxicity. [Poster presentation]. Pennsylvania College of Emergency Physicians, PACEP SA21 
Spivey and CPC Competitions, Virtual. 
This Poster is brought to you for free and open access by LVHN Scholarly Works. It has been accepted for inclusion 
in LVHN Scholarly Works by an authorized administrator. For more information, please contact 
LibraryServices@lvhn.org. 






Duloxetine Poisoning: A Unique Case of Cardiotoxicity  
Derek J. Fikse, DO; Alexandra M. Amaducci, DO; Margaret A. Vido, DO; Robert D. Cannon, DO; Kenneth D. Katz, MD
Lehigh Valley Health Network, Department of Emergency and Hospital Medicine/USF Morsani College of Medicine, Allentown, Pa.
Background
Duloxetine is a SNRI similar to venlafaxine. While cardiotoxicity 
from venlafaxine poisoning has been described, it has not 
previously been reported with duloxetine. 
Case
A 15-year-old boy with PMH of depression and anxiety prescribed 
fluoxetine 20 mg and hydroxyzine 10 mg intentionally ingested 
3,060 mg of his mother’s duloxetine pills. Notable VS were BP 
145/88 and HR 127. On exam, his mental status was normal. He 
was noted to have six beat ankle clonus and hyperreflexia.  
CBC, CMP, VBG, salicylate, acetaminophen, and ethanol were 
unremarkable. Initial EKG demonstrated sinus tachycardia 109 bpm, 
QRS 103 ms, and QTc 462 ms. One hundred ml of 8.4% sodium 
bicarbonate was administered intravenously without any change in 
the QRS duration. Serial EKGs demonstrated gradual prolongation 
of QRS and QTc reaching a maximum of 134 ms and 543 ms, 
respectively. Sodium bicarbonate IV was re-administered, again 
without improvement in the QRS duration. Although his tachycardia 
and serotonergic signs resolved within 12 hours post ingestion, the 
QRS widening persisted with gradual resolution over 84 hours to 
100 ms. He developed neither hemodynamic instability nor 
dysrhythmias. Serum LC/MS detected duloxetine, fluoxetine, 
hydroxyzine, cannabinoids, and caffeine. The patient was  
admitted to inpatient psychiatry on hospital day five. 
Discussion
The patient was prescribed fluoxetine, a potent CYP450 
2D6 inhibitor, which may have inhibited the metabolism 
of duloxetine, also metabolized by CYP450 2D6. 
Although in vitro evidence exists demonstrating 
duloxetine’s ability to block cardiac sodium channels, 
QRS widening or other clinically significant cardiotoxicity 
has not been described. It is also noteworthy that this 
patient’s QRS interval did not improve after sodium 
bicarbonate administration. Neither fluoxetine nor 
hydroxyzine is expected to cause QRS widening. 
Conclusion
Physicians should be aware of the potential for 
duloxetine-induced cardiotoxicity.
